fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Codeine phosphate

2 general benefit · 1 not a benefit

Teva-Codeine · DIN 00593435 · 15 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Codeine · DIN 00593435 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2017-11-17 · brand TEVA-CODEINE · ATC R05DA04 CODEINE · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 15 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Codeine: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0596). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00593435)

Source record
DIN 00593435: Teva-Codeine Raw flags: sec3=Y Item: 280808010; group id 400; item number 0955; lccId None; manufacturer id TEV Source form: Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.0596; ministry $0.0596 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00593435 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6415
Interchangeable products
Codeine · DIN 00779458 · not recorded
Shortage status: resolved shortage (ended August 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00593435
Shortage record checked October 6, 2026

Teva-Codeine · DIN 00593451 · 30 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Teva-Codeine · DIN 00593451 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2017-11-17 · brand TEVA-CODEINE · ATC R05DA04 CODEINE · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 30 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Codeine: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0966). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00593451)

Source record
DIN 00593451: Teva-Codeine Raw flags: sec3=Y Item: 280808011; group id 400; item number 0956; lccId None; manufacturer id TEV Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.0966; ministry $0.0966 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00593451 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6416
Shortage status: resolved shortage (ended April 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00593451
Shortage record checked October 6, 2026

Codeine · DIN 00779458 · 15 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.Discontinued October 1, 2015 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2015-10-01 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Codeine · DIN 00779458 Manufacturer: Rougier Pharma, Division of Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2015-10-01 · brand CODEINE TAB 15MG · ATC R05DA04 CODEINE · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 15 MG · company Rougier pharma division of ratiopharm inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Codeine: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00779458)

Source record
DIN 00779458: Codeine Raw flags: notABenefit=Y, sec3=Y Item: 280808010; group id 400; item number 0955; lccId None; manufacturer id ROG Source form: Tab; strength: 15mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00779458 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9439
Interchangeable products
Teva-Codeine · DIN 00593435 · $0.0596
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00779458
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 1, 2015 — choose a marketed DIN from the same-category list.

Codeine sulfate trihydrate & monohydrate

All strengths: Limited Use, Reason for Use code 201 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 201 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Codeine Contin · DIN 02230302 · 50 mg · CR tablet

Limited Use, Reason for Use code 201 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 201 (criteria below)
Ontario Limited Use criteria, code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02230302 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1997-03-13 · brand CODEINE CONTIN 50MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 50 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Codeine Contin: Formulary list price $0.51 per unit (the source does not state the unit; exact figure $0.5137). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02230302)

Source record
DIN 02230302: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808101; group id 401; item number 0957; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.5137; ministry $0.5137 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02230302 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49057
Shortage status: resolved shortage (ended January 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230302
Shortage record checked October 6, 2026

Codeine Contin · DIN 02163748 · 100 mg · CR tablet

Limited Use, Reason for Use code 201 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 201 (criteria below)
Ontario Limited Use criteria, code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02163748 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1995-12-31 · brand CODEINE CONTIN 100MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 100 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Codeine Contin: Formulary list price $1.03 per unit (the source does not state the unit; exact figure $1.0285). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163748)

Source record
DIN 02163748: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808107; group id 401; item number 0958; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0285; ministry $1.0285 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163748 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19050
Shortage status: resolved shortage (ended July 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163748
Shortage record checked October 6, 2026

Codeine Contin · DIN 02163780 · 150 mg · CR tablet

Limited Use, Reason for Use code 201 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 201 (criteria below)
Ontario Limited Use criteria, code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02163780 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1995-12-31 · brand CODEINE CONTIN 150MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 150 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Codeine Contin: Formulary list price $1.54 per unit (the source does not state the unit; exact figure $1.5434). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163780)

Source record
DIN 02163780: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808108; group id 401; item number 0959; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.5434; ministry $1.5434 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163780 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19051
Shortage status: resolved shortage (ended June 20, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163780
Shortage record checked October 6, 2026

Codeine Contin · DIN 02163799 · 200 mg · CR tablet

Limited Use, Reason for Use code 201 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 201 (criteria below)
Ontario Limited Use criteria, code 201
Reason for Use code 201 For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Codeine Contin · DIN 02163799 Manufacturer: Purdue Pharma; listing date 2002-04-04 Health Canada: Marketed since 1995-12-31 · brand CODEINE CONTIN 200MG CONTROLLED RELEASE TAB · ATC R05DA04 CODEINE · form Tablet (extended-release) · route Oral · ingredients CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) 200 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Codeine Contin: Formulary list price $2.06 per unit (the source does not state the unit; exact figure $2.0571). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163799)

Source record
DIN 02163799: Codeine Contin Raw flags: sec12=Y, sec3=Y Item: 280808109; group id 401; item number 0960; lccId 00066; manufacturer id PFP Source form: CR Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0571; ministry $2.0571 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163799 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19049
Shortage status: resolved shortage (ended January 11, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163799
Shortage record checked October 6, 2026
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg · Cap

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:08 and 1 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults TEVA-CODEINE is indicated for the symptomatic treatment of mild to moderate pain of various causes and the control of exhausting, nonproductive cough which does not respond to non-opioid antitussives. TEVA-CODEINE is not indicated as an as-needed (prn) analgesic. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics). Pediatrics (< 18 years of age) The safety and efficacy of TEVA-CODEINE has not been studied in the pediatric population. The use of TEVA-CODEINE is not recommended in patients between 12 and 18 years of age, and is contraindicated in those under 12. Contraindicated in < 12 years of age for any use: Regardless of the clinical setting, the use of codeine is contraindicated in patients below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see … https://pdf.hres.ca/dpd_pm/00053875.PDF PM date: November 5, 2019 Source product: TEVA-CODEINE; DIN 00593435; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. CODEINE CONTIN is not indicated as an as-needed (prn) analgesic. 1.1 Pediatrics Pediatrics (<18 years of age): Regardless of the clinical setting, codeine, including CODEINE CONTIN, should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see 2 Contraindications; 4 Dosage and Administration; 7.1.3 Pediatrics; 10.3 Pharmacokinetics, Special Populations and Conditions, Pediatrics) CODEINE CONTIN has not been studied in the pediatric population, therefore the use of CODEINE CONTIN is not recommended in patients over 12 and under 18 years of age (see 2 Contraindications). 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. (see 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). In general, dose selecti… https://pdf.hres.ca/dpd_pm/00078791.PDF PM date: 2025-03-04 Source product: CODEINE CONTIN 100MG CONTROLLED RELEASE TAB; DIN 02163748; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Codeine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026